Loading company…
Melbourne-based radiopharmaceutical company developing and selling theranostic imaging and treatment agents for oncology.
Founded in 2015 in Melbourne, Australia, Telix Pharmaceuticals Limited develops and commercializes theranostic radiopharmaceuticals for oncology, combining diagnostic and therapeutic functions. Its imaging agent Illuccix is approved by the US FDA and the Australian TGA for detecting prostate cancer, and Gozellix is under development. Products are sold mainly to hospitals and clinics, chiefly in North America. The company completed an IPO in November 2017 raising AUD 50 million, and CEO David Cade leads it.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in